Hikma takes an exclusive licence to pharma&’s rucaparib for the MENA region

The licensed territory is MENA as a region. No African country is named in the release or in the reporting reviewed, so the African link is the regional definition only and is recorded as such.


Coverage: The Meridian legal market record (editorial).

The licensed territory is MENA as a region. No African country is named in the release or in the reporting reviewed, so the African link is the regional definition only and is recorded as such.

Record ID TX-AFR-2025-0011
Record type Commercial IP transaction
Transaction type Patent licence, Exclusive licence, In-licensing
IP rights patent, trade mark, regulatory data
Status Signed
Qualifying date 2025-04-09
Sector Life sciences · Pharmaceuticals – oncology
African markets Multi-jurisdictional
Licensed territory Middle East and North Africa (MENA); no country list in the release.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, independently corroborated · 3 source(s)
Last verified 2026-10-25

Parties

  • Hikma Pharmaceuticals PLC (United Kingdom): licensee
  • pharmaand GmbH (pharma&) (Austria): licensor

Key terms

  • Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: MENA region

Sources

  1. Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA, Hikma Pharmaceuticals, 2025-04-09
  2. Hikma and pharmaand partnership press release, April 2025, Hikma Pharmaceuticals (PDF release), 2025-04-09
  3. Hikma signs exclusive licensing agreement with pharma and to bring innovative oncology treatment to MENA, MarketScreener, 2025-04-10

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.